Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) Study

G. d'Annunzio University

Status: Completed

Conditions: AKI; Aortic Valve Stenosis; Blood Transfusion; Prognosis; Transcatheter Aortic Valve Implantation (TAVI)

Treatments: Procedure: Blood Transfusion

Study type: Observational

Funder types: Other

Identifiers

NCT03740425

TRITAVI18

Details and patient eligibility

About

Periprocedural bleeding events are frequent during transcatheter aortic valve implantation (TAVI), mainly driven by vascular complications and are associated to a worse prognosis. Therefore, red blood cell (RBC) transfusion is often required, although it is associated with worsened outcomes.

There is no consensus on the optimal transfusion strategy after bleeding. The Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) will be a multicenter retrospective registry enrolling consecutive patients who underwent TAVI; the primary aim of the study will be to test whether RBC transfusion is a marker or an independent predictor of adverse events.

Full description

Periprocedural bleeding events are frequent during transcatheter aortic valve implantation (TAVI), mainly driven by vascular complications and are associated to a worse prognosis. Therefore, red blood cell (RBC) transfusion is often required, although it is associated with worsened outcomes.

There is no consensus on the optimal transfusion strategy after bleeding: among patients undergoing cardiac surgery, the Transfusion Requirements in Cardiac Surgery (TRICS) III trial documented that a restrictive RBC transfusion strategy (if hemoglobin level was <7.5 g/dl) was noninferior to a liberal approach (if hemoglobin level was <9.5 g/dl) with respect to the composite occurrence of death, myocardial infarction (MI), stroke, or new-onset renal failure with dialysis.

The Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) will be a multicenter retrospective registry enrolling consecutive patients who underwent TAVI; the primary aim of the study will be to test whether RBC transfusion is a marker or an independent predictor of adverse events. Patients will be stratified according to their lowest hemoglobin value (>9.5 g/dl, 7.5-9.5 g/dl and <7.5 g/dl) and to whether they received or not periprocedural RBC transfusion.

The primary endpoint will be the 30-day occurrence of major adverse cardiovascular events (MACE), as death, myocardial infarction (MI), stroke, or acute kidney injury (AKI, as absolute increase in serum creatinine ≥0.3 mg/dL [≥26.4 μmol/L] or ≥50% increase ≤72 hours).

Enrollment: 3,235 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients undergoing transcatheter aortic valve implantation (TAVI)

Exclusion criteria

• age<18 years

Trial design

3,235 participants in 2 patient groups

Transfusion

Description:

Patients requiring blood transfusion after transcatheter aortic valve implantation (TAVI)

Treatment:

Procedure: Blood Transfusion

No Transfusion

Description:

Patients not requiring blood transfusion after transcatheter aortic valve implantation (TAVI)

Treatment:

Procedure: Blood Transfusion